Cardiovascular Tests: Use & Limits of Biochemical Markers - Therapeutic Measurements of ADMA Involved in Cardiovascular Disorders

Author(s): Caroline L. Smith, Patrick Vallance

Journal Name: Current Pharmaceutical Design

Volume 11 , Issue 17 , 2005

Become EABM
Become Reviewer


Asymmetric dimethylarginine (ADMA) is an endogenously occurring methylarginine that inhibits nitric oxide synthesis. Plasma levels of methylarginines increase in renal failure and certain cardiovascular pathologies, and in patients with end stage renal failure the level of ADMA predicts the risk of cardiovascular events and overall mortality. The object of this review is to describe the mechanisms of ADMA synthesis, metabolism and uptake and to outline techniques for measuring ADMA and the pathological states in which ADMA levels are altered.

Keywords: nitric oxide (no), nitric oxide synthases (nos), nadph, protein arginine methyltransferases (prmt), single nucleotide polymorphisms (snp), angiogenesis, arginine, cardiovascular disorders, pre-eclampsia

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2005
Page: [2177 - 2185]
Pages: 9
DOI: 10.2174/1381612054367364
Price: $65

Article Metrics

PDF: 1